Volume 91, special issue 4, Numéro spécial, Décembre 2004

ÉDITORIAL

Le cancer du sein, paradigme cancérologique (p.203)
Jean‐Philippe Spano, Paul‐Henri Cottu

Synthèse

Classification of preinvasive breast and carcinoma in situ : doubts, controversies, and proposal for new categorizations (p.205-10)
Marie-Mélanie Dauplat, Frédérique Penault-Llorca

Assessment of HER2 status in breast cancer (p.211-5)
Frédérique Penault-Llorca, Anne Cayre

What is new about sentinel lymph node biopsy in breast cancer? (p.216-20)
Gilles Houvenaeghel, Max Buttarelli, Isabelle Rossi, Agnès Tallet, Jocelyne Jacquemier, Patrice Viens

Sentinel lymph node negative breast cancer larger than 30 mm : is axillary lymph node dissection constantly necessary ? (p.221-5)
Gilles Houvenaeghel, Marc Martino, Max Buttarelli, Vincent Moutardier, Emmanuelle Charaffe Jaufret, Isabelle Rossi, Carole Tarpin, Agnès Tallet, Patrice Viens, Jocelyne Jacquemier

Breast carcinoma and genomic technology: contribution of DNA microarrays (p.226-31)
Nicolas Sévenet, Paul-Henri Cottu

Neoadjuvant treatment of early breast cancer: new drugs contribution (p.232-8)
Sylvie Giacchetti, Caroline Cuvier, Hamid Hocini, Edwige Bourstyn, Anne de Roquancourt, Marc Espié

Aromatase inhibitors in adjuvant setting in breast cancer (p.239-43)
Jean-Philippe Spano, David Khayat, Thierry Delozier

Dose density and dose intensity in the treatment of breast cancer (p.244-53)
Pierre Saintigny, Sabine Assouad, Joseph Gligorov, Frédéric Selle, Henri Roché, Jean-Luc Breau, Jean-François Morère, Jean-Pierre Lotz

Expression of chemokine receptors by cancer cells (p.254-6)
Fabrice André, Jean-Charles Soria, H Assi, Suzy Delaloge, Michel Spielmann

Targeted therapies: last focus on EGF receptor inhibitors in breast cancer (p.257-60)
Nicolas Magné, Gérard Milano